Table 1

Characteristics of participants and practice patterns with IV-Mg in acute asthma

Characteristic, N (%)Canada
N=131
UK/Ireland
N=391
Australia/New Zealand
N=64
Total
N=586
(95% CI)
Years in practice (≥10 years)89 (67.9)128 (32.7)38 (59.4)255 (43.5)(39.1 to 48.1)
Paediatric emergency medicine trained90 (68.7)166 (42.5)44 (68.8)300 (51.2)(47.1 to 55.3)
University-affiliated paediatric ED120 (91.6)245 (62.6)50 (78.1)415 (70.8)(66.9 to 74.5)
Use IV-Mg in refractory acute asthma in ED130 (99.2)381 (97.4)64 (100)575 (98.1)(96.7 to 99.1)
Evidence of IV-Mg benefit about safe discharge after satisfactory and sustained response to IV-Mg adequateStrongly agree:
33 (25.2)
Strongly agree:
3 (0.8)
Strongly agree:
0 (0.0)
Strongly agree:
36 (6.1) (4.3 to 8.4)
Agree:
43 (32.8)
Agree:
19 (4.9)
Agree:
6 (9.4)
Agree:
68 (11.6) (9.1 to 14.4)
Decision to use IV-Mg also prompts hospitalisation, irrespective of clinical response to IV-Mg.Strongly agree:
29 (22.1)
Strongly agree:
248 (63.4)
Strongly agree:
38 (59.4)
Strongly agree:
315 (53.8) (49.6 to 57.9)
Agree:
28 (21.4)
Agree:
124 (31.7)
Agree:
21 (32.8)
Agree:
173 (29.5) (25.8 to 33.4)
Routine hospitalisation after IV-Mg due to inadequate evidence of IV-Mg benefit or concern about discharge safetyStrongly agree/agree:
48/57 (84.2)
Strongly agree/agree:
369/372 (99.2)
Strongly agree/agree:
53/59 (89.8)
Strongly agree/agree:
470/488 (96.3) (94.2 to 97.8)
  • ED, emergency department; IV-Mg, IV magnesium.